Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 4;22(1):95.
doi: 10.1186/s12944-023-01836-w.

Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study

Affiliations

Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study

Solim Essomandan Clémence Bafei et al. Lipids Health Dis. .

Erratum in

Abstract

Background: Dyslipidemia and inflammation are significant factors for the onset of cardiovascular diseases (CVD); however, studies regarding their interactions on the risk of CVD are scarce. This study aimed to assess the interaction of dyslipidemia and high-sensitivity C-reactive protein (hs-CRP) on CVD.

Methods: This prospective cohort enrolled 4,128 adults at baseline in 2009 and followed them up until May 2022 for collecting CVD events. Cox-proportional hazard regression analysis estimated the hazard ratios (HRs) and 95% confidence intervals (CIs) of the associations of increased hs-CRP (≥ 1 mg/L) and dyslipidemia with CVD. The additive interactions were explored using the relative excess risk of interaction (RERI) and the multiplicative interactions were assessed with HRs (95% CI) while the multiplicative interactions were assessed by the HRs (95% CI) of interaction terms.

Results: The HRs of the association between increased hs-CRP and CVD were 1.42 (95% CI: 1.14-1.79) and 1.17 (95% CI: 0.89-1.53) among subjects with normal lipid levels and subjects with dyslipidemia, respectively. Stratified analyses by hs-CRP levels showed that among participants with normal hs-CRP (< 1 mg/L), TC ≥ 240 mg/dL, LDL-C ≥ 160 mg/dL, non-HDL-C ≥ 190 mg/dL, ApoB < 0.7 g/L, and LDL/HDL-C ≥ 2.02 were associated with CVD [HRs (95%CIs): 1.75 (1.21-2.54), 2.16 (1.37-3.41), 1.95 (1.29-2.97), 1.37 (1.01-1.67), and 1.30 (1.00-1.69), all P < 0.05, respectively]. While in the population with increased hs-CRP, only ApoAI > 2.10 g/L had a significant association with CVD [HR (95% CI): 1.69 (1.14-2.51)]. Interaction analyses showed that increased hs-CRP had multiplicative and additive interactions with LDL-C ≥ 160 mg/dL and non-HDL-C ≥ 190 mg/dL on the risk of CVD [HRs (95%CIs): 0.309 (0.153-0.621), and 0.505 (0.295-0.866); RERIs (95%CIs): -1.704 (-3.430-0.021 and - 0.694 (-1.476-0.089), respectively, all P < 0.05].

Conclusion: Overall our findings indicate negative interactions between abnormal blood lipid levels and hs-CRP on the risk of CVD. Further large-scale cohort studies with trajectories measurement of lipids and hs-CRP might verify our results as well explore the biological mechanism behind that interaction.

Keywords: Cardiovascular diseases risk; Dyslipidemia; Interactive effect; hs-CRP.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they have no disclosure of any conflict of interest regarding this manuscript.

Figures

Fig. 1
Fig. 1
Multivariate Cox-regression of lipids and the risk of stroke, CHD, and CVD stratified by hs-CRP levels Notes: *: Significance at 0.05. The statistical significance for the heterogeneity test was set at P < 0.1. The model was adjusted for age, gender, smoking, drinking, hypertension, BMI, and diabetes. BMI: body mass index. Hs-CRP: high sensitivity C-reactive Protein, CHD: coronary heart disease, CVD: cardiovascular disease, TC: total cholesterol, TG: triglycerides, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, BMI: body mass index, ApoAI: apolipoprotein AI, ApoB: apolipoprotein B, Lp(a): lipoprotein(a), HR: hazard ratio, CI: confidence intervals

References

    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. Li JJ, Liu HH, Li S. Landscape of cardiometabolic risk factors in chinese population: a narrative review. Cardiovasc Diabetol. 2022;21(1):113. doi: 10.1186/s12933-022-01551-3. - DOI - PMC - PubMed
    1. Wang A, Liu J, Li C, Gao J, Li X, Chen S, et al. Cumulative exposure to high-sensitivity C-Reactive protein predicts the risk of Cardiovascular Disease. J Am Heart Assoc. 2017;6(10):e005610. doi: 10.1161/JAHA.117.005610. - DOI - PMC - PubMed
    1. Holthuis EI, Visseren FLJ, Bots ML, Peters SAE. Risk factor clusters and Cardiovascular Disease in High-Risk Patients: the UCC-SMART study. Glob Heart. 2021;16(1):85. doi: 10.5334/gh.897. - DOI - PMC - PubMed
    1. Peters SAE, Wang X, Lam TH, Kim HC, Ho S, Ninomiya T, Knuiman M, et al. Clustering of risk factors and the risk of incident cardiovascular disease in asian and caucasian populations: results from the Asia Pacific Cohort Studies collaboration. BMJ Open. 2018;8(3):e019335. doi: 10.1136/bmjopen-2017-019335. - DOI - PMC - PubMed